ReviewCurrent opinion in rheumatology2016
Spectrum of immune-mediated necrotizing myopathies and their treatments.
Review in Current opinion in rheumatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 49 citations in OpenAlex.
- Seronegative Immune-Mediated Necrotizing Myopathy: An Overview for Optimal Clinical Management.Current rheumatology reports · 2026Review
- Statin-Associated Immune-Mediated Necrotizing Myopathy Presenting as Persistent Hypertransaminasemia.Cureus · 2026Article
- When Sepsis Is Not Sepsis: A Case Report of Autoimmune Myopathy Masquerading as Postoperative Infection.Cureus · 2025Article
- Successful treatment of anti-signal recognition particle antibody-positive myositis with intravenous cyclophosphamide: A case report.Fukushima journal of medical science · 2025Article
- Article
- CD163+ macrophage density in perimysial connective tissue associated with prognosis in IMNM.Annals of clinical and translational neurology · 2024Article
- Anti-SRP-positive necrotising myopathy concurrent with breast malignancy.BMJ case reports · 2023Article
- Treatment of Immune-Mediated Necrotizing Myopathy.Current treatment options in rheumatology · 2023Article
- Anti-SRP immune-mediated necrotizing myopathy: A critical review of current concepts.Frontiers in immunology · 2022Review
- A Case Report of Statin-Induced Immune-Mediated Necrotizing Myopathy Treatment Challenges.Case reports in rheumatology · 2022Article
- Therapeutic management of immune-mediated necrotizing myositis.Current treatment options in rheumatology · 2021Article
- Challenges in Treating Statin-Associated Necrotizing Myopathy.Case reports in rheumatology · 2021Article
- A man with fever and bilateral limb weakness.Internal and emergency medicine · 2020Article
- Severe statin-induced autoimmune myopathy successfully treated with intravenous immunoglobulin.BMJ case reports · 2020Article
- Identification of a novel autoantigen eukaryotic initiation factor 3 associated with polymyositis.Rheumatology (Oxford, England) · 2020Article
- [Clinical and pathological characteristics of immune mediated necrotizing myopathy].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2019Article
- Myopathy in a 61-year-old Hispanic man.BMJ case reports · 2019Article
- Immune myopathy with large histiocyte-related myofiber necrosis.Neurology · 2019Article
- The performance of the European League Against Rheumatism/American College of Rheumatology idiopathic inflammatory myopathies classification criteria in an expert-defined 10 year incident cohort.Rheumatology (Oxford, England) · 2019Article
- Safety of statin drugs in patients with dyslipidemia and stable systemic autoimmune myopathies.Rheumatology international · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewThis review aims to describe the spectrum of clinical, histological, and serological features in patients with immune-mediated necrotizing myopathies (IMNMs). RECENT
findingsAutoantibodies recognizing the signal recognition particle (SRP) or 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) define two unique subtypes of necrotizing myositis patient with distinct clinical features. For example, the major histocompatibility class II human leukocyte antigen allele DRB111:01 is a strong immunogenetic risk factor for developing anti-HMGCR autoantibodies whereas B5001 and DQA10104 are over-represented in patients with anti-SRP autoantibodies. Furthermore, statin exposure is a risk factor only for anti-HMGCR autoantibodies. And while skeletal muscle involvement is predominant in most patients with both autoantibodies, lung involvement appears in ∼20% of anti-SRP-positive patients but is more rare in anti-HMGCR-positive patients. Of note, ∼20% of anti-SRP and anti-HMGCR positive patients have significant lymphocytic infiltrates on muscle biopsy and thus would not be formally categorized as having IMNM; aside from this, these patients are clinically indistinguishable from other patients with the same autoantibody profile. SUMMARY: Anti-SRP and anti-HMGCR autoantibodies define unique populations of IMNM patients. It may be more appropriate to subtype myositis patients based on these autoantibodies than on their muscle biopsy features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.